Home>Investment

Multinational pharmaceutical companies based in Pudong accelerate market entry with innovative drugs

english.pudong.gov.cn Updated:2025-04-09

Pudong New Area, a thriving hub for biopharmaceutical innovation in China, is witnessing a surge in drug approvals and investment commitments from multinational pharmaceutical companies.

Recently, Roche's innovative treatment, Ocrevus® (ocrelizumab injection), received approval from China's National Medical Products Administration (NMPA) for the treatment of adult relapsing and primary progressive multiple sclerosis (MS). This marks a significant milestone for MS patients in China, offering them a globally advanced treatment option.

In addition to Roche, other leading multinationals such as Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, and Novartis have also announced new drug approvals or significant investment plans in China. Boehringer Ingelheim, for instance, is accelerating its R&D efforts in China, with plans to invest nearly 5 billion yuan ($687.62 million) over the next five years, aiming to bring innovative therapies to Chinese patients without delay.

These developments underscore Pudong's role as a pivotal center for biopharmaceutical innovation and collaboration, driving forward the healthcare industry's progress in China and beyond.